CytoMed Therapeutics Limited
GDTC · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -1.33 | 0.32 | -0.10 | 0.26 |
| FCF Yield | -2.88% | -2.81% | -1.91% | -4.39% |
| EV / EBITDA | -30.72 | -31.51 | -74.49 | -28.50 |
| Quality | ||||
| ROIC | -8.42% | -8.42% | -17.68% | -5.38% |
| Gross Margin | 93.07% | 93.07% | 174.86% | 89.67% |
| Cash Conversion Ratio | 0.71 | 0.71 | 1.09 | 1.09 |
| Growth | ||||
| Revenue 3-Year CAGR | -4.46% | 2.89% | 11.42% | 40.95% |
| Free Cash Flow Growth | -5.66% | 3.18% | 5.90% | -4.39% |
| Safety | ||||
| Net Debt / EBITDA | 2.31 | 2.31 | 6.84 | 6.84 |
| Interest Coverage | -65.56 | -125.97 | -155.36 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.02 | 0.02 |
| Cash Conversion Cycle | -3,792.81 | -3,792.55 | 5,018.17 | 5,006.43 |